Axel Dietrich

This inventor holds 7 USPTO granted patents, plus 3 CIPO patents and 8 EPO patents. Top assignees: Sanofi, Sanofi-Aventis. Active years: 2012-2015.

USPTO Granted Patents = 7

% Patents Active = 85.7

CIPO Patents = 3

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 6.4

ph-index = 2

Forward Citations = 9(Granted Patents)

Company Filing History:

Years Active: 2012-2015

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9040544 - 2,5-substituted oxazolopyrimidine derivatives (2015-05-26),

2. 8846692 - Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring (2014-09-30),

3. 8846691 - Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring (2014-09-30),

4. 8846690 - Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring (2014-09-30),

5. 8785439 - 2,5,7-substituted oxazolopyrimidine derivatives (2014-07-22),

6. 8748436 - Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring (2014-06-10),

7. 8207146 - Phenothiazine derivative having a double bond, method for the production thereof, and use thereof as a pharmaceutical (2012-06-26),

Title: Innovations of Axel Dietrich

Introduction

Axel Dietrich is a notable inventor based in Frankfurt-am-Main, Germany. He has made significant contributions to the field of pharmaceuticals through his innovative work. His research focuses on the development of new medicinal compounds that can improve health outcomes.

Latest Patents

Dietrich holds a patent for a "Phenothiazine derivative having a double bond, method for the production thereof, and use thereof as a pharmaceutical." This invention relates to substituted phenothiazines with a double bond and their physiologically acceptable salts. The patent highlights their potential use as a medicament, showcasing Dietrich's commitment to advancing medical science.

Career Highlights

Axel Dietrich is currently employed at Sanofi-Aventis, a leading global healthcare company. His work at Sanofi-Aventis allows him to collaborate with other experts in the field and contribute to the development of innovative pharmaceutical solutions.

Collaborations

Some of his coworkers include Stefanie Keil and Elisabeth Defossa. Their collaboration enhances the research environment and fosters the exchange of ideas, which is crucial for innovation.

Conclusion

Axel Dietrich's contributions to the field of pharmaceuticals through his patent and work at Sanofi-Aventis demonstrate his dedication to innovation. His research has the potential to impact the medical community positively.